{"id":"NCT00114777","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant","officialTitle":"Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2008-05","completion":"2014-09","firstPosted":"2005-06-20","resultsPosted":"2017-07-07","lastUpdate":"2017-07-07"},"enrollment":595,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Renal Transplantation"],"interventions":[{"type":"DRUG","name":"Cyclosporin A","otherNames":["CsA"]},{"type":"DRUG","name":"Belatacept Less Intensive Regimen (LI)","otherNames":[]},{"type":"DRUG","name":"Belatacept More Intensive Regimen (MI)","otherNames":[]}],"arms":[{"label":"Cyclosporin A","type":"ACTIVE_COMPARATOR"},{"label":"Belatacept Less Intensive Regimen (LI)","type":"EXPERIMENTAL"},{"label":"Belatacept More Intensive Regimen (MI)","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.","primaryOutcome":{"measure":"Percentage of Participants Who Survived With a Graft at 12 Months Post-Transplant","timeFrame":"Month 12 post-transplant","effectByArm":[{"arm":"Belatacept More Intensive (MI) Regimen","deltaMin":85.9,"sd":null},{"arm":"Belatacept Less Intensive (LI) Regimen","deltaMin":88,"sd":null},{"arm":"Cyclosporin A (CsA)","deltaMin":84.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":79,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Hungary","Italy","Norway","Poland","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["24831918","22300431"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":162,"n":184},"commonTop":["Anaemia","Diarrhoea","Oedema peripheral","Urinary tract infection","Transplant dysfunction"]}}